Literature DB >> 34211002

High expression of DNA damage-inducible transcript 4 (DDIT4) is associated with advanced pathological features in the patients with colorectal cancer.

Fahimeh Fattahi1,2, Leili Saeednejad Zanjani1, Zohreh Habibi Shams3, Jafar Kiani1,2, Mitra Mehrazma1,3, Mohammad Najafi4, Zahra Madjd5,6,7.   

Abstract

DNA damage-inducible transcript 4 (DDIT4) is induced in various cellular stress conditions. This study was conducted to investigate expression and prognostic significance of DDIT4 protein as a biomarker in the patients with colorectal cancer (CRC). PPI network and KEGG pathway analysis were applied to identify hub genes among obtained differentially expressed genes in CRC tissues from three GEO Series. In clinical, expression of DDIT4 as one of hub genes in three subcellular locations was evaluated in 198 CRC tissues using immunohistochemistry method on tissue microarrays. The association between DDIT4 expression and clinicopathological features as well as survival outcomes were analyzed. Results of bioinformatics analysis indicated 14 hub genes enriched in significant pathways according to KEGG pathways analysis among which DDIT4 was selected to evaluate CRC tissues. Overexpression of nuclear DDIT4 protein was found in CRC tissues compared to adjacent normal tissues (P = 0.003). Furthermore, higher nuclear expression of DDIT4 was found to be significantly associated with the reduced tumor differentiation and advanced TNM stages (all, P = 0.009). No significant association was observed between survival outcomes and nuclear expression of DDIT4 in CRC cases. Our findings indicated higher nuclear expression of DDIT4 was significantly associated with more aggressive tumor behavior and more advanced stage of disease in the patients with CRC.

Entities:  

Year:  2021        PMID: 34211002     DOI: 10.1038/s41598-021-92720-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  50 in total

1.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders.

Authors:  Ada Hamosh; Alan F Scott; Joanna Amberger; Carol Bocchini; David Valle; Victor A McKusick
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  Colorectal cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ann Goding Sauer; Stacey A Fedewa; Lynn F Butterly; Joseph C Anderson; Andrea Cercek; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-03-05       Impact factor: 508.702

Review 3.  From tumour heterogeneity to advances in precision treatment of colorectal cancer.

Authors:  Cornelis J A Punt; Miriam Koopman; Louis Vermeulen
Journal:  Nat Rev Clin Oncol       Date:  2016-12-06       Impact factor: 66.675

4.  Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis.

Authors:  Tzipora Shoshani; Alexander Faerman; Igor Mett; Elena Zelin; Tamar Tenne; Svetlana Gorodin; Yana Moshel; Shlomo Elbaz; Andrei Budanov; Ayelet Chajut; Hagar Kalinski; Iris Kamer; Ada Rozen; Orna Mor; Eli Keshet; Dena Leshkowitz; Paz Einat; Rami Skaliter; Elena Feinstein
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

5.  REDD1/DDIT4-independent mTORC1 inhibition and apoptosis by glucocorticoids in thymocytes.

Authors:  Nicholas C Wolff; Renée M McKay; James Brugarolas
Journal:  Mol Cancer Res       Date:  2014-03-10       Impact factor: 5.852

Review 6.  RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders.

Authors:  Mercè Canal; Joan Romaní-Aumedes; Núria Martín-Flores; Víctor Pérez-Fernández; Cristina Malagelada
Journal:  Front Cell Neurosci       Date:  2014-10-02       Impact factor: 5.505

Review 7.  DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer.

Authors:  Indira Tirado-Hurtado; Williams Fajardo; Joseph A Pinto
Journal:  Front Oncol       Date:  2018-04-12       Impact factor: 6.244

Review 8.  Novel biomarkers for the diagnosis and prognosis of colorectal cancer.

Authors:  Hyung-Hoon Oh; Young-Eun Joo
Journal:  Intest Res       Date:  2019-11-30

Review 9.  Biomarkers in colorectal cancer: Current clinical utility and future perspectives.

Authors:  Marco Vacante; Antonio Maria Borzì; Francesco Basile; Antonio Biondi
Journal:  World J Clin Cases       Date:  2018-12-06       Impact factor: 1.337

10.  The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.

Authors:  Martha Foltyn; Anna-Luisa Luger; Nadja I Lorenz; Benedikt Sauer; Michel Mittelbronn; Patrick N Harter; Joachim P Steinbach; Michael W Ronellenfitsch
Journal:  Br J Cancer       Date:  2019-02-12       Impact factor: 7.640

View more
  4 in total

1.  Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression.

Authors:  Leili Saeednejad Zanjani; Monireh Mohsenzadegan; Mahdieh Razmi; Fahimeh Fattahi; Elham Kalantari; Maryam Abolhasani; Sima Saki; Zahra Madjd
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-27       Impact factor: 4.553

2.  Resveratrol inhibits the proliferation, invasion, and migration, and induces the apoptosis of human gastric cancer cells through the MALAT1/miR-383-5p/DDIT4 signaling pathway.

Authors:  Zhuying Yang; Liang Xia
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  Bioinformatic Investigation of Micro RNA-802 Target Genes, Protein Networks, and Its Potential Prognostic Value in Breast Cancer.

Authors:  Maryam Eini; Sepideh Parsi; Mahmood Barati; Golnaz Bahramali; Marziyeh Alizadeh Zarei; Jafar Kiani; Assad Azarnezhad; Arshad Hosseini
Journal:  Avicenna J Med Biotechnol       Date:  2022 Apr-Jun

4.  Identification and Verification of Potential Hub Genes in Amphetamine-Type Stimulant (ATS) and Opioid Dependence by Bioinformatic Analysis.

Authors:  Wei Zhang; Xiaodong Deng; Huan Liu; Jianlin Ke; Mingliang Xiang; Ying Ma; Lixia Zhang; Ming Yang; Yun Liu; Feijun Huang
Journal:  Front Genet       Date:  2022-03-30       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.